Kusum Regmi, FNP

Kusum Regmi practices at Permanente Medical Group Inc in Santa Clara, California.

Kusum Regmi's NPI, 1538705611, was assigned on November 22, 2019. Kusum Regmi holds California license 95013274.

Kusum Regmi's primary practice is Permanente Medical Group Inc, at 710 Lawrence Expy, Santa Clara, CA 95051 in Santa Clara County. The practice phone is (408) 851-1000.

Kusum Regmi's primary practice is Permanente Medical Group Inc in Santa Clara, California. The medical group on file is The Permanente Medical Group, Inc. Dmand AI also links Kusum Regmi to 4 more medical groups, 3 group practices and clinics, 1 physician office and 1 skilled nursing facility, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Kusum Regmi practices, 5 sites in all. Vendor and product names are available with a free account.

Family is Kusum Regmi's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Kusum Regmi is licensed in California.

Dmand AI lists acute skin infection, ankle or foot injury, conjunctivitis, ear eustachian tube disorders, fluid in a joint, head wound, lower back pain and minor injury to a limb among the conditions Kusum Regmi treats.

CMS data shows 259 Medicare services from Kusum Regmi across 2 procedure codes in 2024, for 106 Medicare patients. Medicare paid $19,706 for them. Every service was in an office.

CMS counts 106 Medicare patients who saw Kusum Regmi in 2024. The largest group is 85 and over, with 52 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Kusum Regmi's median patient age at 79, with 57% women.

In 2024, Kusum Regmi wrote 1,359 Medicare Part D claims for 341 patients. 87% of them were for generic drugs. CMS names the drug for 893 of them, across 38 drugs with 11 or more claims each, at $50,732 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Kusum Regmi for performance year 2024, reported as part of a group. Kusum Regmi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 3 general payments to Kusum Regmi from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Neurocrine BioSciences, Inc. paid the most, $124.